Abstract: Provided is an oral Pt(IV) anticancer prodrug containing a 3-bromopyruvate as an axial ligand, with a molecular formula of cis,trans,cis-[Pt(1R,2R-diaminocyclohexane)(OH)(3-bromopyruvate)(C2O4)]. It is a prodrug of oxaliplatin and 3-bromopyruvic acid is a small molecular glycolysis inhibitor. The prodrug is able to simultaneously act on DNA replication and glycolytic pathways of cancer cells, giving full play to the advantage of double-acting targets. The oral Pt(IV) anticancer prodrug is synthesized by using oxaliplatin as a starting material, performing axial oxidation with H2O2 and neutralizing the oxidized product with 3-bromopyruvic acid.

Abstract: Provided are a water-soluble Pd(II) complex, a synthesis method thereof and use thereof as a catalytic precursor. The complex has a chemical name, ammonium dinitrooxalato palladium (II), and a molecular formula of (NH4)2[Pd(NO2)2(C2O4)]·nH2O (n is the number of crystal water). The Pd(II) complex is synthesized by using PdCl2 or [Pd(NH3)2Cl2] as a starting material which is firstly converted into [Pd(NH3)4]Cl2 in ammonium hydroxide, followed by a chemical reaction between [Pd(NH3)4]Cl2 and excessive NaNO2 to produce trans-[Pd(NH3)2(NO2)2] via ligand substitution mechanism, and finally dissolving trans-[Pd(NH3)2(NO2)2] in an aqueous solution of oxalic acid leads to the formation of the target product (NH4)2[Pd(NO2)2(C2O4)]·2H2O. The complex does not contain chlorine and other elements that are harmful to a catalyst, is readily soluble in water and has a low thermal decomposition temperature.